Literature DB >> 4401692

Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis.

O Sjaastad, P Stensrud.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4401692     DOI: 10.1111/j.1600-0404.1972.tb07532.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  8 in total

Review 1.  A basis for migraine therapy- the autonomic theory reappraised.

Authors:  E S Johnson
Journal:  Postgrad Med J       Date:  1978-04       Impact factor: 2.401

2.  Beta-blockers in migraine prophylaxis.

Authors:  M Anthony
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 3.  The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Authors:  V Limmroth; M C Michel
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 4.  Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine.

Authors:  K E Andersson; E Vinge
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Propranolol in the treatment of migraine.

Authors:  T E Wideroe; T Vigander
Journal:  Br Med J       Date:  1974-06-29

6.  A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.

Authors:  Jeffrey L Jackson; Elizabeth Cogbill; Rafael Santana-Davila; Christina Eldredge; William Collier; Andrew Gradall; Neha Sehgal; Jessica Kuester
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

Review 7.  Uses of beta-adrenoceptor blocking drugs.

Authors:  B N Prichard; D G McDevitt; R G Shanks
Journal:  J R Coll Physicians Lond       Date:  1976-10

8.  Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis.

Authors:  Jeffrey L Jackson; Akira Kuriyama; Yachiyo Kuwatsuka; Sarah Nickoloff; Derek Storch; Wilkins Jackson; Zhi-Jiang Zhang; Yasuaki Hayashino
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.